Article Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.

MLA

Festuccia, Claudio, et al. “Article Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.” Cells (2073-4409), vol. 9, no. 1, Jan. 2020, pp. 1–32. EBSCOhost, https://doi.org/10.3390/cells9010032.

APA

Festuccia, C., Mancini, A., Gravina, G. L., Colapietro, A., Vetuschi, A., Pompili, S., Ventura, L., Monache, S. D., Iorio, R., Del Fattore, A., Fogler, W., & Magnani, J. (2020). Article Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth. Cells (2073-4409), 9(1), 1–32. https://doi.org/10.3390/cells9010032

Chicago

Festuccia, Claudio, Andrea Mancini, Giovanni Luca Gravina, Alessandro Colapietro, Antonella Vetuschi, Simona Pompili, Luca Ventura, et al. 2020. “Article Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.” Cells (2073-4409) 9 (1): 1–32. doi:10.3390/cells9010032.